However, the risk of CRC was significantly lower in MSH6 carriers, at 4.7% (95% CI 1.8–7.7%; MLH1 vs. MSH6 p: 0.01; MSH2 and MLH1 p: 0.03). This evidence concerns the gene MSH2 and colorectal carcinoma.